Oxiconazole

Oxiconazole

SCHEMBL601577

Clc1ccc(CON=C(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1.[Ag]

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ERG11

The experimentally established mechanism targets of Oxiconazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 6/20 0.98
CYP2C9 P11712 6/20 0.98
CYP2D6 P10635 4/20 0.98
CYP2C19 P33261 4/20 0.98
PGR P06401 3/20 0.98
CHRM2 P08172 3/20 0.98
ADRA2A P08913 3/20 0.98
ADORA3 P0DMS8 3/20 0.98
CHRM1 P11229 3/20 0.98
ADRB3 P13945 3/20 0.98
IDO1 P14902 3/20 0.98
ADRA2B P18089 3/20 0.98
CHRM3 P20309 3/20 0.98
TACR2 P21452 3/20 0.98
DRD1 P21728 3/20 0.98
ACHE P22303 3/20 0.98
SLC6A2 P23975 3/20 0.98
TBXAS1 P24557 3/20 0.98
HTR2A P28223 3/20 0.98
SLC6A4 P31645 3/20 0.98

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxiconazole SCHEMBL34519 0.99 CYP3A4 (1.00) CYP3A4CYP2C9CYP2D6CYP2C19PGR
Oxiconazole SCHEMBL4540297 0.99 CYP3A4 (1.00) CYP3A4CYP2C9CYP2D6CYP2C19PGR
Oxiconazole SCHEMBL34518 0.99 CYP3A4 (1.00) CYP3A4CYP2C9CYP2D6CYP2C19PGR
Oxiconazole SCHEMBL30416587 0.99 CYP3A4 (1.00) CYP3A4CYP2C9CYP2D6CYP2C19PGR
Oxiconazole SCHEMBL21180321 0.98 CYP3A4 (0.98) CYP3A4CYP2C9CYP2D6CYP2C19PGR
Oxiconazole SCHEMBL18916734 0.93 CYP3A4 (0.88) CYP3A4CYP2C9CYP2D6CYP2C19PGR
SCHEMBL18309812 0.93 IDO1 (0.88) CYP3A4CYP2C9CYP2D6CYP2C19PGR
Oxiconazole SCHEMBL18916735 0.93 CYP3A4 (0.88) CYP3A4CYP2C9CYP2D6CYP2C19PGR
Oxiconazole SCHEMBL153417 0.92 CYP3A4 (1.00) CYP3A4CYP2C9CYP2D6CYP2C19PGR
Oxiconazole SCHEMBL153416 0.92 CYP3A4 (1.00) CYP3A4CYP2C9CYP2D6CYP2C19PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200030477-A1 SYSTEMS, DEVICES, AND METHODS INCLUDING IMPLANTABLE DEVICES WITH ANTI-MICROBIAL PROPERTIES GEARBOX LLC (US) 2020-01-30 US disclosed
US-10426857-B2 Systems, devices, and methods including implantable devices with anti-microbial properties GEARBOX, LLC (US) 2019-10-01 US disclosed
US-20170007733-A1 SYSTEMS, DEVICES, AND METHODS INCLUDING IMPLANTABLE DEVICES WITH ANTI-MICROBIAL PROPERTIES GEARBOX LLC (US) 2017-01-12 US disclosed
US-9474831-B2 Systems, devices, and methods including implantable devices with anti-microbial properties GEARBOX, LLC (US) 2016-10-25 US disclosed
US-20120209090-A1 Systems, devices, and methods including implantable devices with anti-microbial properties SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE SATE OF DELAWARE 2012-08-16 US disclosed
US-20120041286-A1 Systems, devices, and methods including implantable devices with anti-microbial properties SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE 2012-02-16 US disclosed
US-20120041285-A1 Systems, devices, and methods including implantable devices with anti-microbial properties SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE 2012-02-16 US disclosed
US-20120041287-A1 Systems, devices, and methods including implantable devices with anti-microbial properties SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE 2012-02-16 US disclosed
US-20120010481-A1 Systems, devices, and methods including implantable devices with anti-microbial properties SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE 2012-01-12 US disclosed
US-20110275912-A1 Systems, devices, and methods including implantable devices with anti-microbial properties SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE 2011-11-10 US disclosed
US-20110208021-A1 Systems, devices, and methods including implantable devices with anti-microbial properties SEARETE LLC 2011-08-25 US disclosed
EP-1585478-B1 USE OF SYNERGISTIC BACTERIOPHAGE LYTIC ENZYMES FOR PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS UNIV ROCKEFELLER (US) 2010-03-17 EP disclosed
EP-1585478-A4 USE OF SYNERGISTIC BACTERIOPHAGE LYTIC ENZYMES FOR PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS UNIV ROCKEFELLER (US) 2007-09-26 EP disclosed
US-20060159671-A1 Uses of sysnergistic bacteriophage lytic enzymes for prevention and treatment of bacterial infections ROCKEFELER UNIVERSITY 2006-07-20 US disclosed
US-20060073154-A1 Group a streptococci bind to mucin and human pharyngeal cells through a sialic acid-containing receptor THE ROCKFELLER UNIVERSITY 2006-04-06 US disclosed
EP-1585478-A2 USE OF SYNERGISTIC BACTERIOPHAGE LYTIC ENZYMES FOR PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS THE ROCKEFELLER UNIVERSITY (US) 2005-10-19 EP disclosed
WO-2004058182-A2 USE OF SYNERGISTIC BACTERIOPHAGE LYTIC ENZYMES FOR PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS THE ROCKEFELLER UNIVERSITY (US) 2004-07-15 WO disclosed
US-6608187-B2 Homogeneously purified C1 bacteriophage lysin protein or holin protein and a nucleic acids molecule encoding them THE ROCKEFELLER UNIVERSITY 2003-08-19 US disclosed
US-20020058027-A1 C1 bacteriophage lytic system THE ROCKEFELLER UNIVERSITY 2002-05-16 US disclosed
WO-2001090331-A2 C1 BACTERIOPHAGE LYTIC SYSTEM THE ROCKEFELLER UNIVERSITY (US) 2001-11-29 WO disclosed